Interferon is known to have anti-proliferative effects against pancreatic cancer cells and mesothelioma. Unfortunately, clinical evidence for effectiveness is lacking. Most available studies had been in adjuvant settings where the drug’s anti-angiogenic(blood vessel formation) properties may be most prominent. A few metastatic studies do not demonstrate a marked benefit of adding interferon to chemotherapy.
NeoPlas Innovation’s Stephen Cantrell, M.D., has opened a clinic where he uses lovastatin with interferon for a variety of cancer diagnosis. We await peer-reviewed publications on the results of this approach.
Read the Professional version here.